Search
Cincinnati, OH Paid Clinical Trials
A listing of 1120 clinical trials in Cincinnati, OH actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
721 - 732 of 1120
There are currently 1120 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Recruiting
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio +3 locations
Conditions: Small Cell Lung Cancer Extensive Stage
Positive Peers Intervention Clinical Trial
Recruiting
The goal of this clinical trial is to learn if the Positive Peers mobile app intervention increases rates of viral suppression in young (13-34 y/o) persons with HIV.
Does use of the Positive Peers app improve viral suppression among young minority persons with HIV? What user characteristics are associated with a) viral suppression, b) retention in care, and c) perceived HIV-related stigma?
Participants will:
* download the mobile app onto their personal smartphone
* Use the mobile app as they... Read More
Gender:
ALL
Ages:
Between 13 years and 34 years
Trial Updated:
02/21/2025
Locations: Equitas Health, Cincinnati, Ohio
Conditions: HIV Infections
Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery
Recruiting
The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: TriHealth, Cincinnati, Ohio
Conditions: Postoperative Urinary Retention (POUR)
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Cincinnati Cancer Center - 1107, Cincinnati, Ohio
Conditions: Non Small Cell Lung Cancer
REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation With Active Esophageal COOLing: A Sub-Study of the REAL AF Registry
Recruiting
This is a multi-center sub-study examining the effectiveness of active esophageal cooling on subjects undergoing left atrial ablation for symptomatic Paroxysmal Atrial Fibrillation or Persistent Atrial Fibrillation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Christ Hospital, Cincinnati, Ohio
Conditions: Atrial Fibrillation
64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer
Recruiting
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Cincinnati, Cincinnati, Ohio +1 locations
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Study of Olutasidenib and Temozolomide in HGG
Recruiting
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
02/19/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Regional Phenotyping of CF and Non-CF Bronchiectasis
Recruiting
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
02/18/2025
Locations: Penny New, Cincinnati, Ohio
Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
MCG As a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
Recruiting
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/18/2025
Locations: Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio
Conditions: Asthma
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
ALL
Ages:
Between 1 day and 30 days
Trial Updated:
02/18/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Congenital Heart Disease in Children
721 - 732 of 1120